Business Wire

TN-MICROPORT-ORTHOPEDICS

Share
MicroPort Orthopedics Celebrates 20 Years of Stability with its Medial-Pivot Total Knee System

MicroPort Orthopedics Inc. , a medical device company that develops and manufactures cutting-edge joint replacement implants designed to help patients achieve full function faster, is celebrating 20 years of market experience with its medial-pivot total knee system. Since launching in 1998, over 550,000 patients have benefited from MicroPort’s medial-pivot technology, which touts compelling long-term clinical results.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180306005995/en/

“The medial-pivot knee system has now stood the test of time at 20 years demonstrating impressive survivorship and excellent patient satisfaction,” said C. Lowry Barnes, MD, Chair of Orthopedic Surgery at the University of Arkansas for Medical Sciences. “It is important to recognize that this isn’t just one single publication. Over the years, the Advance® and Evolution® Medial-Pivot Knee Systems have been included in over 90 peer-reviewed publications that validate its long-term durability and functionality.”

For many years, orthopedists have clung to the concept of a hinge-like knee design with multiple radii. However, studies show that on average, 20% of patients are not satisfied with the outcome of their total knee replacement. Challenging these traditional knee designs, pioneers such as J. David Blaha, MD, Mr. Michael Freeman, MD, and Richard Komistek, PhD provided kinematic and radiographic evidence supporting medial-pivoting kinematics and stability of the knee, paving the way for the release of MicroPort’s medial-pivot knee system.

“I began using MicroPort’s medial-pivot knee system in May of 1998,” said Joost Lagast, MD, Orthopedic Surgeon at Maria Middelares Hospital Ghent. “At the time, I was not 100% satisfied with my results and was looking for something new. I attended a meeting with Professor Blaha at AAOS and was very impressed with the medial-pivot concept. During my first case, it was love at first sight – the stability and natural motion were unlike anything I’d seen in my practice. Over the last 20 years, I’ve performed nearly 4,000 knee replacement surgeries using the system, and I’m still fantastically in love with it today.”

The Evolution® Medial-Pivot Knee System features medial ball-in-socket articulation and a mobile lateral compartment that pivots about the medial side, enhancing stability, providing high flexion, and allowing the prosthesis to replicate the natural feel and motion of the knee. Additionally, the medial stability of the Evolution® knee substitutes for both the ACL and PCL, allowing for normal quadriceps function and increased proprioception.

Former NFL quarterback and Hall-of-Famer, Terry Bradshaw, underwent total knee replacement surgery with the Evolution® Medial-Pivot Knee. “My knee was causing me all kinds of problems. I couldn’t sleep at night, I couldn’t take the stairs, and worst of all, I had a hard time playing with my granddaughter,” said Bradshaw, now 69 years old. “I underwent surgery on a Tuesday, left the hospital two days later, and was walking without assistance in two weeks. Today, I can do anything I want to do – walking down stairs, squatting, fishing, and golfing. The medial-pivot technology has been life changing for me. It feels just like my knee!”

“MicroPort Orthopedics is proud to celebrate the 20th anniversary of our medial-pivot knee system,” said Aurelio Sahagun, President, MicroPort Orthopedics. “When we launched the system back in 1998, there was nothing else like it on the market – it challenged the basis of traditional designs. Change does not happen often in orthopedics, but at the time, we knew that the medial-pivot concept had the capability to revolutionize total knee replacement. 20 years later, clinical results have proven that this design delivers better outcomes for patients and surgeons. It is incredibly gratifying to offer a best-in-class knee replacement option, and we are looking forward to another 20 years of innovation as we expand the medial-pivot technology into the revision market.”

About MicroPort Orthopedics

Established in January 2014, MicroPort Orthopedics Inc. is a multinational producer of orthopedic products and a proud member of the MicroPort Scientific Corporation family of companies. From its headquarters in Arlington, Tennessee, MicroPort Orthopedics develops, produces, and distributes innovative orthopedic reconstructive products. The company’s U.S.-based manufacturing and logistics capabilities deliver high quality hip and knee products to patients and their doctors in over 60 countries, including the U.S., EMEA, Japan, Latin America, and China markets. For more information about MicroPort Orthopedics, visit http://www.ortho.microport.com/ .

About MicroPort Scientific

MicroPort Scientific Corporation is a leading medical device company focused on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 15 seconds in thousands of major hospitals around the world, MicroPort maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort is dedicated to becoming a patient-oriented global enterprise that improves and reshapes patient lives through application of innovative science and technology. For more information, please refer to: http://www.microport.com .

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words “believe,” “intend,” “expect,” “anticipate,” “project,” “estimate,” “predict,” “is confident,” “has confidence” and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort’s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

Contact:

MicroPort Orthopedics
Alex Piersiak, 617-909-5022
Alex.piersiak@ortho.microport.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA202515.6.2025 09:15:00 CEST | Press release

Data demonstrates the potential for INCA033989 to modify disease by directly inhibiting and eliminating oncogenic mutCALR cells, while sparing healthy cells and restoring normal blood cell productionIn high-risk patients with essential thrombocythemia (ET) with a CALR mutation (mutCALR), 86% of INCA033989-treated patients at doses 400 mg and above achieved a complete or partial hematologic responsewith the majority (82%) realizing a complete responseA reduction in peripheral blood mutCALR variant allele frequency (VAF) was observed in 89% of evaluable patients correlating with hematologic responseInitial results demonstrate a favorable safety profile – no dose limiting toxicities were reported, a maximum tolerated dose was not reached and 98% of patients remained on treatmentIncyte will host an in-person analyst and investor event highlighting this data at EHA today, Sunday, June 15, 2025, from 6:00 - 7:30 a.m. EDT (12:00 -1:30 p.m. CEST) Incyte (Nasdaq:INCY) today announced the first

Perma-Pipe International Holdings, Inc. Announces First Quarter Fiscal 2025 Financial Results13.6.2025 15:14:00 CEST | Press release

The Company generated net sales of $46.7 million compared to $34.3 million in the first quarter of 2024Income before income taxes of $7.4 million versus $2.6 million in the first quarter of 2024Backlog of $131.1 million at April 30, 2025, compared to $63.1 million at April 30, 2024 Perma-Pipe International Holdings, Inc. (NASDAQ: PPIH) announced today financial results for the first quarter ended April 30, 2025. “Sales for the first quarter were $46.7 million, resulting in an increase of $12.4 million, or 36.2%, compared to $34.3 million in the same quarter last year. Net income attributable to common stock of $5.0 million was an increase of $3.6 million, or 243%, compared to $1.4 million in the first quarter of the prior year,” noted President and CEO Saleh Sagr. Backlog currently stands at $131.1 million, a decrease of $7.0 million, compared to $138.1 million at January 31, 2025. However, the Company has experienced a significant increase in backlog of $68.0 million, or 108%, compare

Capcom’s Devil May Cry 5 Sales Top 10 Million Units!13.6.2025 15:00:00 CEST | Press release

– Capcom further enhances global brand awareness with its Single Content Multiple Usage strategy – Capcom Co., Ltd. (TOKYO:9697) today announced that worldwide cumulative sales of Devil May Cry 5 havesurpassed 10 million units. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250613788747/en/ Devil May Cry 5 logo In Devil May Cry 5, players can enjoy thrilling, high-speed gameplay, stylish action, and beautiful graphics, depicted with intricate realism thanks to Capcom’s proprietary RE ENGINE. The title has garnered strong support from users due to its exceptional gameplay experience, leading to expanded sales as a catalog title since its release. Capcom provided an even more advanced story and action elements in the game with the addition of a new playable character, and more recently, on April 3, 2025, the company released the new Devil May Cry animated series on Netflix, in line with the company’s Single Content Multiple Us

realme Summer Party: a Major Event and an Exclusive Collaboration with TikTok13.6.2025 14:59:00 CEST | Press release

realme, one of the world's leading smartphone brands, held a summer festival on June 6 and 7 at the foot of the Eiffel Tower with fun activities. Visitors could try their hand at ring throwing, immortalize their moments at the Photobooth van, or leave with exclusive gifts. Each participant received a voucher to exchange for a prize in the dedicated area for a successful festive experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612984325/en/ Live photo from realme Summer Party and the newly launched GT 7 Dream Edition A festive event at the foot of the Eiffel Tower The event was a great success, thanks to the engagement of participants on-site and through social media. Many visitors shared photos and videos, creating a dynamic and friendly atmosphere, amplified by the realme community. An exclusive collaboration between realme and TikTok This collaboration between realme and TikTok extends beyond this event. Indee

Take It Slow: Why Ireland Is the Perfect Destination for the ‘Unrushed’ Traveller13.6.2025 14:30:00 CEST | Press release

Tourism Ireland--In a world that’s always rushing, Ireland is extending a gentle invitation: take your time. With its winding coastal trails, soul-soothing landscapes, and deep-rooted traditions, Ireland is emerging as one of Europe’s most natural fits for slow tourism — a growing global travel trend focused on deeper, more meaningful experiences over fast-paced itineraries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612345730/en/ Cycling on greenway, County Waterford From misty mornings in the Burren to long afternoons along the Wild Atlantic Way, Ireland rewards those who slow down. Whether it’s connecting with local craftspeople, foraging along the coast, lingering over storytelling sessions in a pub, or staying in family-run farmhouses — the country’s charm reveals itself not in a rush, but in the details. What is ‘Slow Tourism’? Slow tourism encourages travellers to engage more fully with a destination, spending

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye